News

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA completes extraordinary general meeting

(Oslo, Norway, 11 February 2016) Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") has completed the Extraordinary General Meeting (EGM) today which approved the Private Placement and Repair Issue announced on 27 January 2016. As proposed by the Company’s majority shareholder at the EGM, the EGM resolved not to allow oversubscription in the Repair Issue.

Please see the attached minutes from the meeting in Norwegian and English translation as well as a company presentation from the meeting.

The Repair Issue is subject to a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company. All details about the Repair Issue will be set out in the prospectus, expected to be published on or about 16 February 2016.

This information is published in accordance with the requirements of the Continuing Obligations.

Further information
David Horn Solomon, President and CEO, +45 22 20 63 00, dhs@bionorpharma.com
Jens Krøis, CFO, +45 20 80 16 68, jk@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, jfr@bionorpharma.com

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.

Minutes as PDF.
Presentation as PDF.
Announcement as PDF.